Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT01084057
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸South Pasadena Cancer Center, South Pasadena, California, United States
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
- Conditions
- Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Ependymoblastoma
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01076530
- Locations
- 🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 16
- Registration Number
- NCT01075113
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
🇺🇸Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2019-06-04
- Target Recruit Count
- 27
- Registration Number
- NCT01064921
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT01059552
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 30
- Registration Number
- NCT01038388
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2023-02-13
- Target Recruit Count
- 72
- Registration Number
- NCT01023737
- Locations
- 🇺🇸
Cancer Therapy & Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 27
- Registration Number
- NCT01019850
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Lucile Salter Packer Children's Hospital, Palo Alto, California, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01000155
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
- Conditions
- Childhood Burkitt LymphomaChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Diffuse Large Cell Lymphoma
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00994500
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.